Business Wire
Business Wire is not a single author but a news distribution company that disseminates full-text press releases from thousands of companies and organizations worldwide. The articles are typically written in a formal, informational style and are often used by businesses to share news and updates about their products or services.
Biography:
https://en.wikipedia.org/wiki/Business_Wire
86%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
100%
Examples:
No current examples available.
Conflicts of Interest
100%
Examples:
No current examples available.
Contradictions
100%
Examples:
No current examples available.
Deceptions
67%
Examples:
- In the article titled 'New Interim, Real-World Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia (finerenone) for Patients with Chronic Kidney Disease Associated with Type 2 Diabetes', the title promises new insights on Hyperkalemia and safety of Kerendia for patients with Chronic Kidney Disease associated with Type 2 Diabetes, but the body of the article does not contain any information related to this.
Recent Articles
Tesla's Q2 2023 Production and Delivery Figures: Impressive Results and Bullish Stock Trends
Broke On: Tuesday, 02 July 2024Tesla's Q2 2023 production and delivery figures exceed expectations, reaching approximately 411,000 and 444,000 vehicles respectively. This impressive performance has led to a surge in the company's stock price with potential targets at $260, $334, and possibly $400. Despite competition from other EV manufacturers like NIO Inc. and Geely, Tesla continues to innovate its autonomous driving capabilities and expand its market lead. 
New Features and Health Insights in watchOS 11: Live Activities, Sleep Tracking, and More
Broke On: Thursday, 13 June 2024Apple Watch users can expect real-time information from Live Activities on the Lock Screen with watchOS 11, along with new health features like sleep tracking and insights through the Vitals app. However, Series 4, Series 5, and first-generation SE models will not receive this update. Immunotherapy Drugs Jemperli and Pembrolizumab Show Promise in Improving Survival Rates for Certain Bowel Cancer Patients: ASCO 2024
Broke On: Monday, 03 June 2024Immunotherapy drugs Jemperli and pembrolizumab show promising results in improving survival rates for certain bowel cancer patients, potentially replacing or reducing the need for surgery and chemotherapy, according to clinical trial findings presented at ASCO 2024. 
Walgreens Expands Specialty Pharmacy Business with Focus on Gene and Cell Therapies: New Facility, 1,500 Specialty-Trained Pharmacists, and $24 Billion Market
Broke On: Thursday, 25 April 2024Walgreens launches Walgreens Specialty Pharmacy, a $24 billion business focusing on gene and cell therapies, integrating new services with existing assets. The expansion includes an 18,000-sqft facility in Pittsburgh to manage complex supply chains for high-cost treatments like cancer and HIV. With over 1,500 specialty-trained pharmacists and 5,000 patient advocacy team members, Walgreens Specialty Pharmacy aims to improve financial performance through expanded offerings in the specialty pharmacy market. 
New Drug Approved for Treatment of Rare and Serious Condition, Pulmonary Arterial Hypertension (PAH)
Broke On: Wednesday, 27 March 2024A new drug called WINREVAIR has been approved by the FDA for treating pulmonary arterial hypertension (PAH), a rare and fatal condition that affects mostly women. The drug works by regulating a growth factor that is overproduced in PAH patients, potentially altering the disease's biology. WINREVAIR improved exercise capacity and other outcomes in clinical trials compared to background therapy alone. SpaceX Launches Final O3b mPower Satellites Amidst Technical Challenges
Broke On: Sunday, 12 November 2023SpaceX successfully launched the final pair of O3b mPower satellites for SES. The satellites are grappling with electrical issues that have reduced their initial capacity. Boeing will provide an extra two O3b mPower satellites under an amended contract. Semaglutide and Sotagliflozin Show Promising Results for Type 2 Diabetes Patients
Broke On: Friday, 03 November 2023The majority of patients did not experience worsening of their diabetic retinopathy (DR) after initiating semaglutide (Ozempic) to treat their type 2 diabetes (T2D). Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been found to provide kidney and heart benefits in patients with type 2 diabetes and chronic kidney disease. Over a median follow-up of 16 months, sotagliflozin reduced the risk of kidney-related complications by 38% and a cardiorenal composite outcome by 23%. Zoliflodacin: A New Antibiotic for Treating Gonorrhea
Broke On: Friday, 03 November 2023A new antibiotic, zoliflodacin, has shown promise in treating gonorrhea. The drug was tested in a clinical trial across 16 sites in five nations, with 930 participants. Zoliflodacin had comparable potency in curing uncomplicated gonorrhea infections as the standard treatment, but was less effective against throat infections. The AIDS Healthcare Foundation (AHF) has praised the promising clinical trial results for zoliflodacin.
